ORAGENICS INC
OGEN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for OGEN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OGEN
Oragenics Inc. is a clinical-stage biopharmaceutical company focused on developing ONP-002, a novel treatment for concussion/mild traumatic brain injury, currently operating with limited cash and a history of operating losses.
Key risk: Cash runway uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for ORAGENICS INC.
Similar companies
Oragenics Inc. is a clinical-stage biopharmaceutical company focused on developing ONP-002, a novel treatment for concussion/mild traumatic brain injury, currently operating with limited cash and a history of operating losses.
- Oragenics is advancing ONP-002, a product candidate for concussion/mild traumatic brain injury, toward Phase II clinical trials and IND-enabling work [sec_mda · as of 2026-03-16].
- As of June 30, 2026, the company reported cash & equivalents of $3.9M and a net loss of -$2.5M for the quarter [sec].
- The company had an accumulated deficit of $226.6 million as of December 31, 2025 [sec_mda · as of 2026-03-16].
- Oragenics expects to incur substantial expenditures to further develop its neurology assets and may seek additional equity, debt, or partnership financing to support its operations [sec_mda · as of 2026-08-13].
What works
- Oragenics has a defined product candidate, ONP-002, targeting a large unmet medical need in concussion/mild traumatic brain injury, with plans to advance it into Phase II trials [sec_mda · as of 2026-03-16].
- The company is actively pursuing strategic partnerships, acquisitions, and licensing arrangements to support its pipeline and potentially provide non-dilutive funding [sec_mda · as of 2026-08-13].
What to weigh
- Oragenics has a limited cash position of $3.9M as of June 30, 2026, and expects to require additional capital to complete planned clinical trials, regulatory filings, and any future commercialization efforts [sec] [sec_mda · as of 2026-08-13].
- The company has a history of operating losses and an accumulated deficit of $226.6 million as of December 31, 2025, with expectations of continued losses for the foreseeable future [sec_mda · as of 2026-03-16].
- There is substantial doubt about the company's ability to continue as a going concern if it cannot secure sufficient additional financing [sec_mda · as of 2026-03-16].
From the filings
Quoted directly from source documents.
The company's accumulated deficit was $226.6 million as of December 31, 2025.
“As of December 31, 2025, our accumulated deficit was $226.6 million.”
SEC MD&A · March 16, 2026
Oragenics plans to advance ONP-002 toward Phase II clinical trials.
“we plan to continue advancing the ONP-002 toward Phase II clinical trials and further IND-enabling work”
SEC MD&A · March 16, 2026
Additional capital is required to complete planned clinical trials and commercialization.
“Additional capital will still be required to complete planned clinical trials, regulatory filings, and any future commercialization efforts.”
SEC MD&A · August 13, 2026
Risks & what to watch (4)›
Key risks
- Cash runway uncertainty — With $3.9M cash as of June 30, 2026, the company may need additional funding before the end of 2026 to sustain operations [sec] [sec_mda · as of 2026-08-13].
- Going concern risk — Substantial doubt exists about the company's ability to continue as a going concern if it cannot secure sufficient capital [sec_mda · as of 2026-03-16].
- Dilution from financing — Raising funds through equity or convertible securities could result in significant dilution to existing shareholders [sec_mda · as of 2026-08-13].
- Clinical development delays — Uncertainties in clinical development, regulatory timelines, and partnership negotiations could delay ONP-002's progress [sec_mda · as of 2026-05-08].
What to watch
- Progress of ONP-002 toward Phase II clinical trials and IND submission [sec_mda · as of 2026-03-16].
- Ability to secure additional financing, including equity, debt, or strategic partnerships [sec_mda · as of 2026-08-13].
- Cash burn rate and whether the company can extend its runway beyond the end of 2026 [sec_mda · as of 2026-08-13].
- Any updates on licensing or collaboration agreements that could provide non-dilutive funding [sec_mda · as of 2026-08-13].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run ORAGENICS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ORAGENICS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
6.0 months
D/E 0.50 · 0% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
14
Total value held
$48K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 65,072 | $36K |
| two sigma securities, llc | 20,343 | $11K |
| blackrock, inc. | 703 | $394 |
| harbour investments, inc. | 34 | $19 |
| wells fargo & company/mn | 34 | $19 |
| hrt financial lp | 18,672 | $10 |
| sbi securities co., ltd. | 11 | $6 |
| keating financial advisory services, inc. | 1 | $1 |
| strategic wealth partners, ltd. | 1 | $1 |
| johnson financial group, inc. | 1 | $1 |
Showing top 10 of 14 institutional holders of ORAGENICS INC. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 16.2%
- Days to cover
- 7.2
- Shares short
- 703,470
- Daily short volume (Aug 27, 2026)
- 43.2%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
OGEN short interestGovernance
Frequently asked questions
What is the AI investment thesis for ORAGENICS INC?
Oragenics Inc. is a clinical-stage biopharmaceutical company focused on developing ONP-002, a novel treatment for concussion/mild traumatic brain injury, currently operating with limited cash and a history of operating losses.
What is ORAGENICS INC's lead drug candidate?
ORAGENICS INC's most advanced tracked candidate is onp-002 (Phase 2) for mild traumatic brain injury ("mTBI" or "concussion").
Who is the CEO of ORAGENICS INC?
Ms. Janet Huffman is the chief executive officer of ORAGENICS INC (OGEN).
Where is ORAGENICS INC headquartered?
ORAGENICS INC (OGEN) is headquartered in Lakewood Ranch, FL, United States.
What therapeutic areas does ORAGENICS INC focus on?
ORAGENICS INC develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.